Related Experiment Videos
[Herceptin-based therapy for breast cancer]
Yutaka Tokuda1, Yuki Saito, Yasuhiro Suzuki
1Department of Breast Cancer and Endocrine Surgery, Tokai University School of Medicine.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 15, 2006
Summary
Trastuzumab is a key drug for HER2-positive breast cancer, but its optimal use in treatment algorithms for both early and metastatic stages requires further review and discussion.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Context:
- HER2 gene amplification occurs in ~30% of breast cancers, correlating with poorer survival.
- HER2 protein overexpression presents a target for antibody-based cancer therapies.
- Trastuzumab, an anti-HER2 monoclonal antibody, is a cornerstone treatment for HER2-positive metastatic breast cancer (MBC).
Purpose:
- To review and discuss the optimal positioning of trastuzumab within treatment algorithms.
- To address the ongoing controversies surrounding trastuzumab's clinical application.
- To provide insights based on clinical experience for both early and metastatic HER2-positive breast cancer.
Summary:
- HER2 gene alterations impact breast cancer prognosis, highlighting the HER2 protein as a therapeutic target.
- Trastuzumab has significantly advanced treatment for HER2-positive breast cancer.
- This review examines trastuzumab's role in treatment strategies for early-stage and metastatic HER2-positive breast cancer.
Impact:
- Clarifying trastuzumab's optimal use can improve treatment efficacy for HER2-positive breast cancer patients.
- Addressing treatment controversies may lead to more standardized and effective therapeutic approaches.
- Evidence-based positioning of trastuzumab can enhance disease-free and overall survival in HER2-positive breast cancer.